BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0025
+0.0002 (8.70%)
Jan 20, 2026, 5:29 PM CET
-52.83%
Market Cap1.63M
Revenue (ttm)-2.39M
Net Income (ttm)-4.00M
Shares Out652.86M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume552,127
Average Volume1,486,290
Open0.0023
Previous Close0.0023
Day's Range0.0023 - 0.0025
52-Week Range0.0012 - 0.0058
Beta-2.41
RSI50.04
Earnings DateApr 27, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jean-Luc Vandebroek
Employees 7
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements

News

There is no news available yet.